(VIANEWS) - TeklaLife Sciences Investors (HQL), Medalist Diversified REIT (MDRR), Lumen Technologies (LUMN) have the highest dividend yield stocks on this list.
| Rank | Financial Asset | Price | Change | Forward Dividend Yield | Updated (EST) |
|---|---|---|---|---|---|
| 1 | TeklaLife Sciences Investors (HQL) | 13.70 | -2.21% | 10.64% | 2022-09-30 07:12:05 |
| 2 | Medalist Diversified REIT (MDRR) | 0.81 | -2.55% | 9.47% | 2022-09-25 05:09:07 |
| 3 | Lumen Technologies (LUMN) | 6.68 | -3.68% | 8.63% | 2022-10-07 14:37:53 |
| 4 | HNI Corporation (HNI) | 27.14 | -2.55% | 4.65% | 2022-09-30 05:14:05 |
| 5 | Astrazeneca (AZN) | 55.38 | 0.85% | 2.15% | 2022-10-07 14:55:57 |
Close to 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. TeklaLife Sciences Investors (HQL) - Dividend Yield: 10.64%
TeklaLife Sciences Investors's last close was $13.70, 36.69% under its 52-week high of $21.64.
Tekla Life Sciences Investors, a closed-ended equity mutual funds launched by Tekla Capital Management LLC and managed is Tekla Capital Management LLC. It invests in all public equity markets around the world. The fund invests in shares of life science companies, such as those in biotechnology, pharmaceutical and diagnostics. This fund invests mainly in small-cap growth stocks. The fund employs fundamental analysis, with an emphasis on market positioning for products or services, business experience, technical expertise and the ability to either generate capital internally or secure external sources of capital. It compares its portfolio's performance against both the NASDAQ Biotech Index (S&P 500 Index) and the S&P 500 Index (S&P 500 Index). It used to be known previously as H&Q Life Sciences Investors Fund. Tekla Life Sciences Investors was established on February 20, 1992. It is based in the United States.
Earnings Per Share
As for profitability, TeklaLife Sciences Investors has a trailing twelve months EPS of $-1.72.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -9.23%.Volume
Today's last reported volume for TeklaLife Sciences Investors is 35900 which is 51.82% below its average volume of 74514.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.5%, now sitting on 2.61M for the twelve trailing months.
Moving Average
TeklaLife Sciences Investors's worth is below its 50-day moving average of $14.96 and way under its 200-day moving average of $15.98.More news about TeklaLife Sciences Investors.
2. Medalist Diversified REIT (MDRR) - Dividend Yield: 9.47%
Medalist Diversified REIT's last close was $0.81, 47.81% below its 52-week high of $1.55.
Medalist Diversified REIT Inc. was a Maryland company that was established on September 28, 2015. We believe we've operated in a way that qualifies us for real estate investment trust (A "REITA") and have chosen to be subject to federal income taxes as REITs. Medalist Diversified Holdings LP, which was established as a Delaware limited partnership in September 2015, is our company's general partner. The company's primary purpose is to purchase, reposition and renovate income-producing properties. It was founded as a Delaware limited partnership on September 29, 2015.
Earnings Per Share
As for profitability, Medalist Diversified REIT has a trailing twelve months EPS of $-0.197.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -14.5%.More news about Medalist Diversified REIT.
3. Lumen Technologies (LUMN) - Dividend Yield: 8.63%
Lumen Technologies's last close was $6.70, 55.66% below its 52-week high of $15.11.
Lumen Technologies, Inc. is a technology-based communications and technology company that provides integrated products and services to residential and business customers across the United States. It operates in two markets: Mass Markets and Business. The company offers cloud and application services such as colocation and server services, managed security services and content delivery services. It also provides IP and data services including Ethernet, VPN, Internet Protocol (IP) and voice over the internet protocol. It also offers fiber infrastructure services, which include high-bandwidth optical wavelength networks and unlit optic fiber. It also offers voice and other services. This includes private line services that are specifically designed to connect two or more organizations; traditional time division multiplexing voice service portfolios; and synchronous optical network based Ethernet and legacy data hosting. The company had approximately 4.5million broadband subscribers as of December 31, 2021. The former name of the company was CenturyLink, Inc., but it changed its name in September 2020 to Lumen Technologies, Inc. Lumen Technologies, Inc. is located in Monroe, Louisiana.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-0.71.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.68%.Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 6, 2022, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 8.63%.
Volume
Today's last reported volume for Lumen Technologies is 20071100 which is 51.95% above its average volume of 13208400.
Moving Average
Lumen Technologies's value is way under its 50-day moving average of $11.33 and way below its 200-day moving average of $11.96.More news about Lumen Technologies.
4. HNI Corporation (HNI) - Dividend Yield: 4.65%
HNI Corporation's last close was $27.14, 39.01% below its 52-week high of $44.50.
HNI Corporation manufactures and sells office furniture in America, Canada, China and Hong Kong. The Office Furniture segment includes a variety of home and commercial furniture including panel-based as well as freestanding, modular, and storage systems. It also offers architectural products, such HON, Allsteel and Beyond brands, Gunlocke and Maxon, HBF and OFM, Respawn and Lamex. The segment also sells products directly to customers, federal, state and local governments, independent dealers, wholesalers and distributors of office products. Hearth Products is a division of the company that offers inserts and stoves for gas, pellet, wood and electric fireplaces. It also sells facings and other accessories primarily designed for use at home under Heatilator and Heat Glo brands. The segment sells its products via independent distributors and retailers, as well as through corporate distribution. HNI Corporation was founded in 1944. It is located in Muscatine in Iowa.
Earnings Per Share
As for profitability, HNI Corporation has a trailing twelve months EPS of $1.66.
PE Ratio
HNI Corporation has a trailing twelve months price to earnings ratio of 16.35. Meaning, the purchaser of the share is investing $16.35 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.02%.Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 24, 2022, the estimated forward annual dividend rate is 1.28 and the estimated forward annual dividend yield is 4.65%.
Volume
Today's last reported volume for HNI Corporation is 184384 which is 22.88% above its average volume of 150044.
More news about HNI Corporation.
5. Astrazeneca (AZN) - Dividend Yield: 2.15%
Astrazeneca's last close was $55.40, 22.73% under its 52-week high of $71.70.
AstraZeneca PLC is a biopharmaceutical firm that specializes in the development, manufacture, and marketing of prescription drugs. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Synagis is a respiratory syncytialvirus treatment; Fluenz Tetra/FluMist quadrivalent for Influenza; Serocort IR/Seroquel XR to treat schizophrenia bipolar disorder; Nexium and Losec/Prilosec are gastroenterology treatments; Vaxzevria, Soliris and Strensiq are covid-19 medications. Through distributors and representative offices located in Europe, Americas, Asia and Africa, the company provides primary and specialty care doctors with services. The company has a partnership agreement with Regeneron Pharmaceuticals, Inc. for research, development, and marketing small molecule medications for obesity. Neurimmune AG will develop and market NI006 and Ionis Pharmaceuticals, Inc. for eplontersen, a liver targeted antisense treatment in Phase III for treatment of transthyretin. Proteros Biostructures GmbH and Sierra Oncology, Inc. will jointly develop and market AZD5153. The company used to be known as Zeneca Group PLC. In April 1999, it changed its name from AstraZeneca PLC. AstraZeneca Plc was founded in 1992. It is located in Cambridge, United Kingdom.
Earnings Per Share
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.52.
PE Ratio
Astrazeneca has a trailing twelve months price to earnings ratio of 36.54. Meaning, the purchaser of the share is investing $36.54 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.84%.Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 23, 2022, the estimated forward annual dividend rate is 1.44 and the estimated forward annual dividend yield is 2.15%.
Moving Average
Astrazeneca's value is way below its 50-day moving average of $62.60 and way below its 200-day moving average of $62.67.Yearly Top and Bottom Value
Astrazeneca's stock is valued at $55.38 at 20:15 EST, way under its 52-week high of $71.70 and higher than its 52-week low of $52.65.
Sales Growth
Astrazeneca's sales growth is 27.7% for the current quarter and 5.9% for the next.
More news about Astrazeneca.